The untapped potential of digital pathology in prostate cancer diagnosis and medical education in sub-Saharan Africa
ConclusionA transition to digital pathology in sub-Saharan Africa could yield incremental benefits to the quality of pathology diagnosis and highlight the growing capacity of digital pathology as a sub-speciality educational tool in the training of African pathologists both in prostate pathology and other pathology sub-specializations.
Publication date: Available online 27 March 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Srinivasa R. Rao, Nasullah K. Alham, Elysia Upton, Stacey McIntyre, Richard J. Bryant, Lucia Cerundolo, Emma Bowes, Stephanie Jones, Molly Browne, Ian Mills, Alastair Lamb, Ian Tomlinson, David Wedge, Lisa Browning, Korsuk Sirinukunwattana, Claire Palles, Freddie C. Hamdy, Jens Rittscher, Clare Verrill
Publication date: Available online 27 March 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Haisong Tan, Nan Hou, Yanlei Liu, Bin Liu, Wen Cao, Dachao Zheng, Wenzhi Li, Yushan Liu, Bin Xu, Zhong Wang, Daxiang Cui
AbstractMultiparametric MRI (mpMRI) of the prostate has been firmly established as a tool in the diagnosis, management, and treatment of prostate cancer. The growth in this field over the past decade has led to increased acceptance and demand for multiparametric prostate MRI across the world. However, with the rising demand for prostate mpMRI, it will become increasingly necessary to train a generation of dedicated prostate imagers to yield a high-quality product.
Conclusions: The recently developed MRI ADC map-based radiomics model was validated in terms of its predictive accuracy of BCR and bRFS after prostatectomy in an external cohort.
Publication date: Available online 27 March 2020Source: Academic RadiologyAuthor(s): Harrison Kim, John V. Thomas, Jeffrey W. Nix, Jennifer B. Gordetsky, Yufeng Li, Soroush Rais-Bahrami
Stereotactic ablative radiotherapy (SABR) of oligometastatic disease was superior to observation in men with hormone-sensitive prostate cancer.Medscape Medical News
Conclusion: Our outcomes support equivalent efficacy and similar risk of adverse effects between apalutamide, enzalutamide, and darolutamide, supporting the use of these antiandrogen agents in high-risk of progression nmCRPC.
A form of highly focused, intense radiation therapy called stereotactic ablative...Read more on AuntMinnie.comRelated Reading: PSMA-PET/CT again shows prowess for prostate cancer MRI-targeted biopsy optimizes prostate cancer detection ASTRO: SABR generates immune response to prostate cancer SABR plus surgery is effective for treating lung cancer ASTRO: SABR is effective for oligometastatic cancers
Prostate-specific membrane antigen PET/CT was found to be a suitable replacement for conventional imaging in patients with prostate cancer, providing superior accuracy to the combined findings of CT and bone scanning.
(Impact Journals LLC) Oncotarget Volume 11, Issue 12 reported outside its natural niche, the cultured prostate cancer stem cells lost their tumor-inducing capability and stem cell marker expression after approximately 8 transfers at a 1:3 split ratio.